The Global Eosinophilic Esophagitis Market, by Drug Class (Corticosteroids: Budesonide {Jorveza and Off-label budesonide} and Fluticasone; Proton Pump Inhibitor (PPI): Omeprazole, Esomeprazole, and Others; and Late Stage Pipeline Drugs: Dupixent, APT-1011, Lirentelimab (AK002), Cendakimab, Etrasimod, TAK-721, and Omilancor (BT-11)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 138.4 Mn in 2021 and is expected to exhibit a CAGR of 33.3% during the forecast period (2021-2028), as highlighted in a new report published by Coherent Market Insights.
Inorganic growth strategies of market players, such as acquisition and collaboration, are expected to drive the global eosinophilic esophagitis market growth over the forecast period. For instance, in May 2019, EsoCap AG is developing a novel smart drug delivery technology collaborated with LTS Lohmann Therapy-Systeme AG a company offers the innovative drug delivery system to cooperate on the industrial development of a drug delivery technology for diseases of the upper gastrointestinal tract.
In addition, increasing approvals for newer products is expected to drive the market growth. For instance, on October 8, 2021, Tezepelumab was granted Orphan Drug Designation (ODD) in the U.S. by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE). Tezepelumab is a human monoclonal antibody developed by AstraZeneca in collaboration with Amgen
Global Eosinophilic Esophagitis Market– Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) pandemic was first reported on December 31, 2019 in Wuhan, China. The World Health Organization (WHO) declared the COVID-19 a pandemic on March 11, 2020. The pandemic caused disruptions in conducting clinical trials. This led to delay in product approvals and thereby hindered the market growth. The COVID-19 pandemic has also affected the economy by directly affecting the production and demand, creating disruptions in distribution channels, and causing a negative financial impact on companies and financial markets.
Browse 29 Market Data Tables and 38 Figures spread through 207 Pages and in-depth TOC on “Global Eosinophilic Esophagitis Market”- Forecast to 2028, by Drug Class (Corticosteroids: Budesonide {Jorveza and Off-label budesonide} and Fluticasone; Proton Pump Inhibitor (PPI): Omeprazole, Esomeprazole, and Others; and Late Stage Pipeline Drugs: Dupixent, APT-1011, Lirentelimab (AK002), Cendakimab, Etrasimod, TAK-721, and Omilancor (BT-11)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the Global Eosinophilic Esophagitis Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/eosinophilic-esophagitis-market-4909
Increasing funding and investments to initiate clinical trials associated with eosinophilic esophagitis (EoE) is expected to drive the market growth. For instance, in November 2021, the Children’s Hospital of Philadelphia (CHOP) received funding of US$ 2 million from the Mondre and Lane families to launch a new clinical trial at the CHOP for patients suffering from severe food allergies such as eosinophilic esophagitis (EoE).
Key Takeaways of the Global Eosinophilic Esophagitis Market:
- The global eosinophilic esophagitis market is expected to exhibit a CAGR of 33.3% during the forecast period. Strong focus on launching new products in the market is expected to drive the global eosinophilic esophagitis market growth over the forecast period. For instance, England and Wales' National Institute for Health and Care Excellence (NICE), an executive non-departmental public body of the Department of Health in England, approved Jorveza budesonide orodispersible tablet for the treatment of eosinophilic esophagitis in adults on June 23, 2021
- Based on drug class, the proton pump inhibitor (PPI) segment is expected to exhibit the highest CAGR in the global eosinophilic esophagitis market over the forecast period. Market players are focused on manufacturing PPI for the treatment of EoE which is expected to drive the market growth over the forecast period. For instance, Glenmark Pharmaceuticals a pharmaceutical company engaged in manufacturing Omeprazole, a PPI for the treatment of reflux-mediated esophageal eosinophilia.
- Among distribution channels, the hospital pharmacies segment is expected to register the highest CAGR over the forecast period in the global esophageal eosinophilia market, as the majority of eosinophilic esophagitis (EoE) drugs is sold by hospital pharmacies
- Among regions, Asia Pacific is anticipated to expand at the highest CAGR in the global eosinophilic esophagitis (EoE) market over the forecast period. Strong focus of key players on growth strategies such as collaboration, acquisition, etc. in the Asia Pacific region is expected to drive the market growth. For instance, in May 2021, Landos Biopharma, Inc. a late clinical-stage biopharmaceutical company entered into an exclusive collaboration and license agreement with LianBio, a biotechnology company dedicated to bringing the medicines for patients in China and other major Asian markets, for the development and commercialization of omilancor and NX-13 in Greater China (mainland China, Hong Kong, Taiwan, and Macau) and other selected Asian countries.
- Major players operating in the global eosinophilic esophagitis (EoE) market include Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Limited, AstraZeneca Plc, Sanofi S.A., Arena Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Revolo Biotherapeutics, Allakos Inc., Bristol-Myers Squibb Co, Calypso Biotech, DBV Technologies, Landos Biopharma, Inc., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Quorum Innovations LLC, and Dr. Falk Pharma GmbH
